Gilead's Sofosbuvir for Hepatitis C Meets Primary Endpoint in Fourth Pivotal Phase 3 Study
Feb 19, 2013 - Gilead Sciences today announced topline results from the Phase 3 FUSION study evaluating 12- and 16-week courses of therapy with the once-daily nucleotide sofosbuvir plus ribavirin in treatment-experienced patients with genotype 2 or 3 chronic hepatitis C virus infection who failed prior treatment.
Join the discussion below, or Read more at Drugs.com.
#1 Feb 19, 2013
Thank God, thank God and good doctors
Add your comments below
|Appalachian congressmen ask FDA to reclassify O... (May '07)||28 min||Ron Paul Liberty||37|
|CDC panel again advises against FluMist||Jun 22||VACCINES MAIM KILL||1|
|Gov't report: Efforts to reduce US uninsured st...||May '17||kuda||22|
|Ring-ring: Cellphone interrupts Supreme Court h...||Apr '17||better call Saul||1|
|Mumps outbreak probably isn't related to vaccin...||Apr '17||MMR||1|
|Bristol Palin says abstinence best path for teens (May '09)||Apr '17||Coonway Tweety||2,658|
|After Trump rally, equity investors move into h...||Mar '17||Retribution||6|
Find what you want!
Search Biotech Forum Now
Copyright © 2017 Topix LLC